Abbreviations:
MH, pain
angiotensin-converting enzymefull analysis setper protocol setvisual analog scaleThe study will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the principles of Good Clinical Practice (GCP), and all of the applicable regulatory requirements. Ethics approval is overseen by Hiroshima University Certified Review Board (reference approval number CRB6180006). Written informed consent will be obtained from all participants before any study procedure is performed. The participant (and/or parent) will have the opportunity to review the Participant Consent Form and agree that they fully understand the details of the study procedures. Informed consent will be administered by a suitably qualified and experienced individual who has been delegated this duty by the principal investigator.The Participant Consent Form was approved by Hiroshima University Certified Review Board to inform participants and their families that the results will be submitted for publication in a scientific journal. Participants will not be identifiable in any publications. The results will be disseminated via presentations to the community and publication in peer-reviewed journals.Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.The authors have no conflicts of interest to disclose.This study is conducted with the free supply of the research drug (Firazyl® subcutaneous injection 30 mg syringe) from Takeda Pharmaceuticals International AG, a subsidiary of Takeda Pharmaceutical Company Limited under Grant Number IIR-JP-002565 (ST and MH). Personnel in Takeda Pharmaceuticals International AG and Takeda Pharmaceutical Company Limited is not involved in the data management, statistical analyses, or auditing of the study. This study is also supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP19ek0410059 (ST and MH).How to cite this article: Takahagi S, Hide M, Aoyama Y, Fukunaga A, Murota H. A single-blind, randomized, crossover study on the efficacy of icatibant for sweating-induced dermal pain (icatibant for sweating-induced dermal pain). 